Recent News

• 11.13.2025 - Q3 2025 Earnings
• 08.14.2025 - Q2 2025 Earnings
• 05.28.2025 - Annual General Meeting 2025
• 05.08.2025 - Q1 2025 Earnings
• 03.27.2025 - Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer
• 03.26.2025 - Alvotech Reports Record Results for 2024 and Provides Business Update
• 03.26.2025 - UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)
• 03.20.2025 - Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
• 03.18.2025 - Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
• 03.13.2025 - March 12, 2025 9:30 PM EDT - March 12, 2025 9:55 PM EDT : Barclays 27th Annual Global Healthcare Conference Miami

Recent Filings

• 03.26.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.26.2025 - EX-99.1 EX-99.1
• 03.20.2025 - EX-99.1 EX-99.1
• 03.20.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.18.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.18.2025 - EX-99.1 EX-99.1
• 02.24.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]